Royalty Pharma Plc Class A (RPRX)
RPRX · Health Care · 
United States
Royalty Pharma Plc Class A (RPRX) is a US company in the Health Care sector. The stock has its largest weight in XUHL (MSCI USA Health Care), at 0.40%. Anyone who holds an ETF containing Royalty Pharma Plc also has an indirect stake in the company.
Data and Charts: Royalty Pharma Plc
Key Data for Royalty Pharma Plc
Royalty Pharma Plc Stock Price Chart
The Royalty Pharma Plc chart shows daily closing prices and is set to the current year by default. The stock is up 73.9% year to date and up 81.9% over twelve months. The last recorded close on October 30, 2026, was $67.18, at 100% of the 52-week range.
Price series from our database since Aug 12, 2024, 558 daily values.
Royalty Pharma Plc Stock Performance
| Year to date | +73.9% | 1 year | +81.9% |
|---|---|---|---|
| 1 month | +15.1% | 3 months | +15.0% |
| Calendar year 2025 | +51.5% |
Measured in euros, Royalty Pharma Plc is up 82.9% year to date and up 88.0% over twelve months. The difference from the dollar figures above comes from the exchange rate alone. Each daily price is converted at the ECB euro reference rate for that day.
Alysly Data Analysis: Royalty Pharma Plc
What ETF Is Royalty Pharma Plc In?
Royalty Pharma Plc has above-average ETF coverage and is held by 20 of the 104 ETFs we track, which together follow 10 indices. That puts the stock in more ETFs than 80.9% of the 4,341 stocks we track.
| ETF | Index | Weight | per €1,000 in the ETF |
|---|---|---|---|
| XUHL / XUHC | MSCI USA Health Care | 0.40% | €4.03 |
| SPFS | MSCI World Health Care | 0.30% | €3.00 |
| XDWH | MSCI World Health Care | 0.30% | €2.98 |
| XDEV | MSCI World Value | 0.17% | €1.70 |
| XDEM | MSCI World Momentum | 0.14% | €1.40 |
| 2B7K | MSCI World SRI | 0.13% | €1.30 |
| WVAL | MSCI World Value | 0.10% | €1.02 |
| XD9U / XD9D | MSCI USA | 0.04% | €0.41 |
| SWWD | MSCI World | 0.04% | €0.40 |
| SPPW | MSCI World | 0.04% | €0.40 |
| EUNL | MSCI World | 0.03% | €0.30 |
| XDWD / XDWL | MSCI World | 0.03% | €0.30 |
| WIMI | MSCI World IMI | 0.03% | €0.27 |
| SPYY | MSCI ACWI | 0.03% | €0.25 |
| IUSQ | MSCI ACWI | 0.02% | €0.20 |
| SPYI / SPSA | MSCI ACWI IMI | 0.01% | €0.07 |
The last column shows how much of €1,000 in one of these funds goes to Royalty Pharma Plc, based on each fund's latest holdings list.
US-listed ETFs holding Royalty Pharma Plc (weight per latest SEC filing): VYM 0.10%, ONEQ 0.05%. These funds are registered in the US; retail investors in the EU usually cannot buy them.
Royalty Pharma Plc Weight in iShares Core MSCI World (EUNL) Since 2020
In iShares Core MSCI World (EUNL), Royalty Pharma Plc had a weight of 0.01% on Dec 31, 2020 and 0.03% on Oct 30, 2026. The fund tracks the MSCI World. Its share peaked at 0.03% on Jun 30, 2022. The weight rises and falls with the stock's price performance relative to the other index members. It can also change when the index provider adjusts the index composition.
What's Inside Your ETF Portfolio and the ETF overlap check show how much Royalty Pharma Plc overlaps with the rest of a portfolio.
What Royalty Pharma Plc Executives and Directors Traded Recently
| Date | Person | Type | Shares | Price |
|---|---|---|---|---|
| Oct 5, 2026 | Urist Marshall Officer, EVP, Research & Investments | Sell (plan) | 4,126 | $57.10 |
| Sep 28, 2026 | Urist Marshall Officer, EVP, Research & Investments | Sell (plan) | 4,126 | $57.88 |
| Sep 22, 2026 | Hite Christopher Officer, EVP & Chairman, Partnering | Sell (plan) | 3,927 | $58.93 |
| Sep 22, 2026 | Hite Christopher Officer, EVP & Chairman, Partnering | Sell (plan) | 96,073 | $58.51 |
The table shows open-market purchases and sales reported over the past 90 days. Directors, officers and shareholders owning more than ten percent must report such transactions within two trading days. Awards and option exercises are excluded.
“Plan” means the transaction follows a schedule set up in advance under Rule 10b5-1. Sales consistently outnumber purchases in these filings because a large part of executive pay is granted in shares. For comparison: over the period covered, executives and directors reported sales at 271 of 350 tracked companies and purchases at 32.
Stocks With ETF Exposure Similar to Royalty Pharma Plc
| Stock | Shared ETFs | r | 1 year | Annualized volatility | Net margin | Revenue growth |
|---|---|---|---|---|---|---|
| Royalty Pharma Plc | – | – | +81.9% | 23.4% | 32.4% | +5.1% |
 Roivant Sciences | 17 | – | +88.5% | 39.4% | -3,629.2% | -71.6% |
 Revolution Medicines | 17 | – | +225.0% | 56.2% | – | – |
 Biogen | 20 | – | +69.5% | 32.1% | 13.1% | +2.2% |
 United Therapeutics Corporation | 18 | – | +32.0% | 41.2% | 41.9% | +10.6% |
| Centene Corporation | 20 | – | +95.5% | 50.4% | -3.4% | +19.4% |
 Insmed Incorporated | 16 | – | -42.0% | 54.9% | -210.5% | +66.7% |
 Medline | 16 | – | – | 43.8% | 4.1% | +11.5% |
 Natera | 16 | – | +114.4% | 46.7% | -9.0% | +35.9% |
These stocks reach a portfolio through largely the same funds as Royalty Pharma Plc. “Shared ETFs” counts the funds that hold both.
Return and volatility are calculated from our daily closing prices in US dollars. Margin and growth come from each company's latest SEC annual filing. Because fiscal years do not end on the same date for every company, the underlying periods are not fully identical.
Fundamental Analysis: Royalty Pharma Plc
Royalty Pharma Plc Key Financials
Figures come from the SEC annual filing for the latest reported fiscal year (period end Dec 31, 2025).
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| FY ended Dec 2023 | 2.4 | 1.1 | 48.2% |
| FY ended Dec 2024 | 2.3 | 0.9 | 37.9% |
| FY ended Dec 2025 | 2.4 | 0.8 | 32.4% |
Technical Analysis: Royalty Pharma Plc
Royalty Pharma Plc Risk Metrics
The close on Oct 30, 2026, was the highest since our series began on Aug 12, 2024. When the S&P 500 rose or fell 1%, Royalty Pharma Plc moved 0.20% on average in the same direction (past 252 trading days). The correlation of 0.11, however, shows only a moderate link to the broad market. Accordingly, moves in the S&P 500 explain only a small part of the daily price moves of Royalty Pharma Plc.
What Royalty Pharma Plc Correlates With
| Instrument | r | −1 … +1 |
|---|---|---|
| Amgen Inc. | +0.72 | |
| AbbVie Inc. | +0.65 | |
| Gilead Sciences Inc. | +0.64 | |
| Eli Lilly and Company | +0.63 | |
| Bristol-Myers Squibb Company | +0.62 | |
| Vertex Pharmaceuticals Incorporated | +0.62 | |
| YB | -0.43 | |
| Eaton Corp. Plc | -0.38 | |
| nVent Electric plc | -0.38 |
The strongest co-movers are listed at the top, the strongest inverse movers at the bottom. Low or negative correlations can help spread risk more broadly across a portfolio.
